A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-29. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
== Further reading == Moss J, Stanley SJ, Oppenheimer NJ (1979). "Substrate specificity and partial purification of a stereospecific NAD- and guanidine-dependent ADP-ribosyltransferase from avian erythrocytes". J. Biol. Chem. 254 (18): 8891–4. doi:10.1016/S0021-9258(19)86783-2. PMID 225315. Moss J, Stanley SJ, Watkins PA (1980). "Isolation and properties of an NAD- and guanidine-dependent ADP-ribosyltransferase from turkey erythrocytes". J. Biol. Chem. 255 (12): 5838–40. doi:10.1016/S0021-9258(19)70705-4. PMID 6247348. Ueda K, Hayaishi O (1985). "ADP-ribosylation". Annu. Rev. Biochem. 54 (1): 73–100. doi:10.1146/annurev.bi.54.070185.000445. PMID 3927821.
Chinese hamster ovary cell Mouse myeloma lymphoblstoid (e.g. NS0 cell) Fully Human Human embryonic kidney cells (HEK-293) Human embryonic retinal cells (Crucell's Per.C6) Human amniocyte cells (Glycotope and CEVEC)
==== Environmental analysis ==== GC-EI-MS has been successfully used for the determination of pesticide residues in fresh food by a single injection analysis. In this analysis 81 multi-class pesticide residues were identified in vegetables. For this study the pesticides were extracted with dichloromethane and further analyzed using gas chromatography–tandem mass spectrometry (GC–MS–MS). The optimum ionization method can be identified as EI or chemical ionization (CI) for this single injection of the extract. This method is fast, simple and cost effective since high numbers of pesticides can be determined by GC with a single injection, considerably reducing the total time for the analysis.
Sources: en.wikipedia.org
Pan frying (sauté) on stove top heat: 120 °C (248 °F) Deep frying: 160–180 °C (320–356 °F) Oven baking: Average of 180 °C (356 °F) Smoke point decreases at a different pace in different oils. Considerably above the temperature of the smoke point is the flash point, the point at which the vapours from the oil can ignite in air, given an ignition source. The following table presents smoke points of various fats and oils.
Eukaryotic cells were created some 2.2 billion years ago in a process called eukaryogenesis. This is widely agreed to have involved symbiogenesis, in which an archaean and a bacterium came together to create the first eukaryotic common ancestor. It evolved into a population of single-celled organisms that included the last eukaryotic common ancestor, gaining capabilities along the way. This cell had a new level of complexity, with a nucleus and facultatively aerobic mitochondria. It featured at least one centriole and cilium, sex (meiosis and syngamy), peroxisomes, and a dormant cyst with a cell wall of chitin and/or cellulose. The last eukaryotic common ancestor gave rise to the eukaryotes' crown group, containing the ancestors of animals, fungi, plants, and a diverse range of single-celled organisms. The green plants were created around 1.6 billion years ago with a second episode of symbiogenesis that added chloroplasts, derived from cyanobacteria.
In some groups of mixotrophic protists, like some dinoflagellates (e.g. Dinophysis), chloroplasts are separated from a captured alga and used temporarily. These klepto chloroplasts may only have a lifetime of a few days and are then replaced.
Sources: en.wikipedia.org
=== Gene-first === The gene-first hypothesis proposes that the first living systems were self-replicating informational molecules, most likely RNA, capable of both storing genetic information and catalyzing chemical reactions. Under this model, simple self-replicating molecules would evolve under selective pressures into increasingly complex organisms. A key advantage of the gene-first hypothesis is that a single molecule capable of template-directed replication can evolve readily if modifications breed true, whereas metabolic networks are fundamentally resistant to evolutionary change. An autocatalytic network is a set of chemical reactions where the products of some reactions act as catalysts to accelerate other reactions in the same network. In simpler terms, chemicals in the network help each other form more chemicals, creating a self-sustaining and self-replicating system. A common challenge in metabolism-first origin-of-life theories is that chemical networks without genes tend to resist change. Imagine a system where one chemical (A) helps make a second chemical (B), and this second chemical (B) helps make more of the first (A). This creates a self-replicating loop but is hard to evolve because even if a better version of the first chemical (A') appears, the system only makes the original kind (B), not the improved one (B'). For this system to evolve, the better first (A`) chemical would also need to help make a better second chemical (B'), which then helps make more of the better first chemical (A'), a very unlikely chain.
State institutions that were allowed to perform sterilizations on patients that seemed like the perfect candidate, was very common. Current research shows that Latinas were targets for sterilization at higher rates than white women. The disproportion among sterilization rates in the Latino community could not be quantified in its current time, but data from sterilization forms suggest that 88 percent of Californians with a Spanish last name were of Mexican origin and descent. The surnames of people in forms recommending institutionalized patients between 1920 and 1945 shows that Latino were more likely to be sterilized than non-Latino men and Latina women experienced sterilization at higher rates than non-Latina women. This data shows that there was an unfair application of the California law that allowed institutions to take health measures for other people on their behalf.
The dye molecules bind to proteins, including those in wool (keratin), to form a protein–dye complex. The formation of the complex stabilises the negatively charged anionic form of the dye, producing the blue colour, even under acid conditions when most of the molecules in solution are in the cationic form. This is the basis of the Bradford assay, which quantifies protein by Coomassie brilliant blue dye binding. The binding of the dye to a protein causes a shift in the absorbance maximum of the dye from 465 to 595 nm. The increase of absorption at 595 nm is monitored to determine protein concentration. The dye also forms a complex with the anionic detergent sodium dodecylsulfate (SDS). The formation of this complex stabilizes the neutral, green form of the dye. This effect can interfere with the estimation of protein concentration using the Bradford assay. It is also likely that the anionic detergent competes with the dye for binding to the protein.
=== Cytoplasmic condensates === Lewy bodies Stress granule P-body Germline P-granules – oskar Starch granules Glycogen granules Frodosomes (Dact1) Corneal lens formation and cataracts Other cytoplasmic inclusions such as pigment granules or cytoplasmic crystals Purinosomes Misfolded protein aggregation such as amyloid fibrils or mutant Haemoglobin S (HbS) fibres in sickle cell disease Signalosomes, such as the supramolecular assemblies in the Wnt signaling pathway. It can also be argued that cytoskeletal filaments form by a polymerisation process similar to phase separation, except ordered into filamentous networks instead of amorphous droplets or granules. Bacteria Ribonucleoprotein Bodies (BR-bodies)- In recent studies it has been shown that bacteria RNA degradosomes can assemble into phase-separated structures, termed bacterial ribonucleoprotein bodies (BR-bodies), with many analogous properties to eukaryotic processing bodies (P-bodies) and stress granules. FLOE1 granules: FLOE1 is a prion-like seed-specific protein that controls plant seed germination via phase separation into biomolecular condensates. Perinuclear compartment
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.